TisCRT-LAPC: A phase II study of tislelizumab combined with nab-paclitaxel and gemcitabine (AG) followed by consolidative radiotherapy in locally advanced pancreatic cancer (LAPC)

被引：0
|
作者：
Guo, Xi
Zhou, Yuhong
Ji, Yuan
Lou, Wenhui
Wu, Lili
Wang, Wenquan
机构：
[1] Fudan Univ, Zhongshan Hosp, Dept Med Oncol, Shanghai, Peoples R China
[2] Fudan Univ, Zhongshan Hosp, Dept Pathol, Shanghai, Peoples R China
[3] Fudan Univ, Zhongshan Hosp, Dept Gen Surg, Shanghai, Peoples R China
[4] Fudan Univ, Zhongshan Hosp, Dept Radiol, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16350
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Secondary resectability in locally advanced pancreatic cancer (LAPC) after nab-paclitaxel/gemcitabine- versus FOLFIRINOX-based induction chemotherapy: Interim results of a randomized phase II AIO trial (NEOLAP).
    Kunzmann, Volker
    Martens, Uwe Marc
    Alguel, Hana
    Siveke, Jens T.
    Goekkurt, Eray
    Pelzer, Uwe
    Siegler, Gabriele Margareta
    Hennes, Elke
    Waldschmidt, Dirk
    Jakobs, Ralf
    Ferenczy, Peter
    Keller, Ralph
    Boeck, Stefan Hubert
    Kullmann, Frank
    Kapp, Markus
    Germer, Christoph Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [32] Interim health related quality of life (QoL) from LAPACT, a Phase 2 trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC)
    Portales, F.
    Philip, P. A.
    Hammel, P.
    Buscaglia, M.
    Pazo-Cid, R.
    Manzano Mozo, J. L.
    Kim, E. S.
    Dowden, S.
    Zakari, A.
    Borg, C.
    Terrebonne, E.
    Rivera Herrero, F.
    Li, J. Shiansong
    Ong, T. J.
    Nydam, T.
    Lacy, J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [33] Phase II study of Yale modified FOLFIRINOX (mFOLFIRINOX) in locally advanced pancreatic cancer (LAPC).
    Stein, Stacey
    Cong, Xiangyu
    Yao, Xiaopan
    Hahn, Carol
    Li, Jia
    Kortmansky, Jeremy S.
    Chang, Bryan William
    Cha, Charles
    Salem, Ronald R.
    Hochster, Howard S.
    Lacy, Jill
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [34] Conversion rate in locally advanced pancreatic cancer (LAPC) after nab-paclitaxel/gemcitabine- or FOLFIRINOX-based induction chemotherapy (NEOLAP): Final results of a multicenter randomised phase II AIO trial
    Kunzmann, V.
    Alguel, H.
    Goekkurt, E.
    Siegler, G. M.
    Martens, U. M.
    Waldschmidt, D.
    Pelzer, U.
    Hennes, E.
    Fuchs, M.
    Siveke, J.
    Kullmann, F.
    Boeck, S.
    Ettrich, T. J.
    Ferenczy, P.
    Keller, R.
    Germer, C-T.
    Stein, H.
    Hartlapp, I.
    Klein, I.
    Heinemann, V.
    ANNALS OF ONCOLOGY, 2019, 30 : 253 - 253
  • [35] Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer
    Suguru Yamada
    Tsutomu Fujii
    Yukihiro Yokoyama
    Hiroki Kawashima
    Osamu Maeda
    Kojiro Suzuki
    Tohru Okada
    Eizaburo Ono
    Junpei Yamaguchi
    Nao Takano
    Hideki Takami
    Masamichi Hayashi
    Yukiko Niwa
    Yoshiki Hirooka
    Yoshiyuki Ito
    Shinji Naganawa
    Yuichi Ando
    Masato Nagino
    Hidemi Goto
    Yasuhiro Kodera
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 815 - 821
  • [36] Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer
    Yamada, Suguru
    Fujii, Tsutomu
    Yokoyama, Yukihiro
    Kawashima, Hiroki
    Maeda, Osamu
    Suzuki, Kojiro
    Okada, Tohru
    Ono, Eizaburo
    Yamaguchi, Junpei
    Takano, Nao
    Takami, Hideki
    Hayashi, Masamichi
    Niwa, Yukiko
    Hirooka, Yoshiki
    Ito, Yoshiyuki
    Naganawa, Shinji
    Ando, Yuichi
    Nagino, Masato
    Goto, Hidemi
    Kodera, Yasuhiro
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (05) : 815 - 821
  • [37] Gemcitabine/Nab-Paclitaxel versus FOLFIRINOX in Locally Advanced Pancreatic Cancer: A European Multicenter Study
    Williet, Nicolas
    Petrillo, Angelica
    Roth, Gael
    Ghidini, Michele
    Petrova, Mila
    Forestier, Julien
    Lopez, Anthony
    Thoor, Audrey
    Weislinger, Lucie
    De Vita, Ferdinando
    Taieb, Julien
    Phelip, Jean Marc
    CANCERS, 2021, 13 (11)
  • [38] A phase III trial of tumor treating fields with nab-paclitaxel and gemcitabine for front-line treatment of locally-advanced pancreatic adenocarcinoma (LAPC): PANOVA-3
    Picozzi, V. J.
    Macarulla Mercade, T.
    Philip, P. A.
    Becerra, C. R.
    Dragovich, T.
    ANNALS OF ONCOLOGY, 2020, 31 : S955 - S955
  • [39] Phase I study of nab-paclitaxel and gemcitabine combination in patients with advanced pancreatic cancer
    Drengler, R. L.
    Smith, L. S.
    Wood, T. E.
    Borad, M. J.
    Ramanathan, R. K.
    Laheru, D. A.
    Hidalgo, M.
    Von Hoff, D. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [40] Phase Ib study of gemcitabine, nab-paclitaxel, and ficlatuzumab in patients with advanced pancreatic cancer
    Perez, Kimberly
    Weekes, Colin D.
    Cleary, James M.
    Abrams, Thomas Adam
    Blaszkowsky, Lawrence Scott
    Enzinger, Peter C.
    Giannakis, Marios
    Goyal, Lipika
    Meyerhardt, Jeffrey A.
    Rubinson, Douglas Adam
    Yurgelun, Matthew B.
    Stonely, Danielle
    Raghavan, Srivatsan
    Bakir, Basil
    Das, Koushik
    Pitarresi, Jason
    Aguirre, Andrew
    Needle, Michael N.
    Rustgi, Anil
    Wolpin, Brian M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
12345